Eisai Inc.'s President And CEO To Retire
In his role as chairman and CEO, Mr. Matsue will be responsible for the strategic direction of the Americas Region.
Eisai President and CEO to Retire
Eisai Inc. has announced the appointments of Yuji Matsue as chairman and chief executive officer and Shaji Procida as president and chief operating officer, effective April 1, 2014.
Eisai and Biogen Idec Enter Collaboration to Develop and...
TOKYO & CAMBRIDGE, Mass. -- -- Eisai Co., Ltd. and Biogen Idec announced today that they have entered into a collaboration to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease , E2609 and BAN2401.
Customer Interaction Solutions
Eisai and Biogen Idec Enter Collaboration to Develop and Commercialize Alzheimer's Disease Treatments
Eisai Co., Ltd. and Biogen Idec announced today that they have entered into a collaboration to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease , E2609 and BAN2401.
SADIF Analytics releases new rating update reports for USA stocks 1
Ilhavo, Portugal - SADIF Investment Analytics, announces a new rating update report covering the following companies: Report Summary for: Koninklijke Ahold N.V. is an average quality company with a positive outlook.
Eisai Announces Launch of Pariet(R) Triple Formulation Combination...
Eisai Co., Ltd. announced today that it will launch two types of triple formulation combination packs that contain its proton pump inhibitor Pariet in Japan on February 14 for use in Helicobacter pylori eradication.
Global Amyotrophic Lateral Sclerosis Market 2014-2018
Reportstack, provider of premium market research reports announces the addition of Global Amyotrophic Lateral Sclerosis Market 2014-2018 market report to its offering Analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period 2013-2018.